✦ LIBER ✦

Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70

✍ Scribed by Gusella, Milena; Bononi, Antonio; Modena, Yasmina; Bertolaso, Laura; Franceschetti, Paola; Menon, Daniela; Pezzolo, Elisa; Barile, Carmen; Crepaldi, Giorgio; Bolzonella, Caterina; Inno, Alessandro; Padrini, Roberto; Pasini, Felice

Book ID: 121544941
Publisher: Springer
Year: 2014
Tongue: English
Weight: 400 KB
Volume: 73
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2378-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8028 Safety analysis of trabectedin in c

8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older

✍ Vergote, I.; Vermorken, J.; Pujade-Lauraine, E.; Monk, B.; Lisyanskaya, A.; Rols 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Impact of geriatric risk factors on pegy

Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial

✍ Falandry, C.; Brain, E.; Bonnefoy, M.; Mefti, F.; Jovenin, N.; Rigal, O.; Guille 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 438 KB